BioMarin Pharmaceuticals Inc
BMRNBioMarin Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases. Founded in 1997, it specializes in treatments for conditions such as enzyme deficiencies, genetic disorders, and other underserved medical needs, offering its products primarily in the areas of neurology, inherited metabolic disorders, and hematology.
Company News
The article identifies 10 stocks positioned to deliver strong returns in 2026 across growth, value, and income categories. These include payment processor Visa, adtech firm The Trade Desk, social media giant Meta, healthcare conglomerate UnitedHealth Group, satellite radio operator Sirius XM, drug developer BioMarin Pharmaceutical, utility NextEr...
Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (u...
BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion on Friday. The acquisition is expected to accelerate revenue growth and be accretive to earnings within 12 months. Analysts view the deal favorably, with Truist Securities raising its price target from $80 to $100. The acquisition adds two revenue-generating rare disea...
The pulmonary emphysema market is projected to grow steadily by 2034, driven by increasing COPD prevalence, an aging population, and advances in therapeutic treatments. Emerging therapies and innovative drugs are expected to transform the market landscape.
The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.
